Another bidder, which remains unidentified, dropped out of the bidding process. Analysts at William Blair now think it ...

Terns Pharmaceuticals (NASDAQ: TERN) had a more memorable March than a great many other companies on U.S. stock exchanges.

Regulatory filings show that Terns ultimately accepted an offer 15% lower than a previous proposal as four companies vied for ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings ...

On April 13, UBS analyst Michael Yee lifted the firm’s price recommendation on Merck & Co., Inc. (NYSE:MRK) to $145 from $130 ...

Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Terns Pharmaceuticals, Inc. (NasdaqGS: TERN) to Merck (NYSE: MRK). Under the terms of the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash ...

Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical giant works on beefing up its cancer portfolio before a key patent on ...

The Company granted 23,316 restricted stock units (the “RSUs”), in the aggregate, of Terns common stock to the new employees. The RSUs vest over four years, subject to the employees’ continued service ...